Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Receivables (2016 - 2019)

Theravance Biopharma (TBPH) has disclosed Change in Receivables for 7 consecutive years, with -$86000.0 as the latest value for Q4 2019.

  • Quarterly Change in Receivables rose 96.42% to -$86000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was -$620000.0 through Dec 2019, up 62.03% year-over-year, with the annual reading at -$620000.0 for FY2019, 62.03% up from the prior year.
  • Change in Receivables for Q4 2019 was -$86000.0 at Theravance Biopharma, up from -$145000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $1.5 million in Q2 2018, with the low at -$2.4 million in Q4 2018.
  • Average Change in Receivables over 5 years is -$14450.0, with a median of $45500.0 recorded in 2015.
  • The sharpest move saw Change in Receivables crashed 4368.18% in 2016, then skyrocketed 1192.92% in 2018.
  • Over 5 years, Change in Receivables stood at $1.1 million in 2015, then plummeted by 119.93% to -$227000.0 in 2016, then surged by 398.24% to $677000.0 in 2017, then tumbled by 455.1% to -$2.4 million in 2018, then surged by 96.42% to -$86000.0 in 2019.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$86000.0, -$145000.0, and $118000.0 for Q4 2019, Q3 2019, and Q2 2019 respectively.